Changes in Hong Kong stocks | Innovative drug concept stocks have been severely disrupted across the board. The US bans China's access to the NIH core biomedical database, agency says innovative drugs are not affected by tariffs for the time being

Zhitong Finance App learned that innovative drug concept stocks fell sharply across the board. As of press release, Deqi Pharmaceutical-B (06996) fell 28.31% to HK$2.33; Heplatinum Pharmaceutical-B (02142) fell 22.91% to HK$5.82; Hehuang Pharmaceutical (00013) fell 18.37% to HK$20; Goli Pharmaceutical-B (01672) fell 18.15% to HK$5.32; Cinda Biotech (01801) fell 16.82% to HK$41.8.

According to the news, according to a report by Yicai, the US National Institutes of Health (NIH) Director's Office website published measures to enhance the security of NIH controlled access data. Starting last Friday (4th), institutions in concerned countries such as China, Russia, and Iran will be prohibited from accessing NIH controlled access data storage and related data. These include key data platforms such as dbGap, the “human genotype-phenotype database” platform, and Anvil, a cloud platform for large-scale genetic data analysis. These platforms have the world's most core human genome, phenotype information, and disease research data, and are databases that researchers around the world have relied on for a long time.

CITIC Construction Investment believes that under the impact of the tariff policy, the impact on the pharmaceutical industry chain is complicated, and there may still be variables. In the current tariffs imposed by the US on China, pharmaceuticals are not involved. At the moment, the bank is optimistic about the innovative drug industry, which is not affected by tariffs for the time being. In the long run, going overseas should still be an important strategic direction for pharmaceutical companies, and we are firmly optimistic about the incremental opportunities that going overseas brings.